190 related articles for article (PubMed ID: 36322453)
21. Further evidence that a variant of the gene NUDT15 may be an important predictor of azathioprine-induced toxicity in Chinese subjects: a case report.
Ailing Z; Jing Y; Jingli L; Yun X; Xiaojian Z
J Clin Pharm Ther; 2016 Oct; 41(5):572-4. PubMed ID: 27381176
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenomics of thiopurines: distribution of TPMT and NUDT15 polymorphisms in the Brazilian Amazon.
Ferreira GMA; Ribeiro Elias AB; Nascimento J; Monteiro WM; Melo GC; Baia-da-Silva DC; Lacerda MVG; Suarez-Kurtz G
Pharmacogenet Genomics; 2020 Oct; 30(8):184-189. PubMed ID: 32453263
[TBL] [Abstract][Full Text] [Related]
23. Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease.
Walker GJ; Harrison JW; Heap GA; Voskuil MD; Andersen V; Anderson CA; Ananthakrishnan AN; Barrett JC; Beaugerie L; Bewshea CM; Cole AT; Cummings FR; Daly MJ; Ellul P; Fedorak RN; Festen EAM; Florin TH; Gaya DR; Halfvarson J; Hart AL; Heerasing NM; Hendy P; Irving PM; Jones SE; Koskela J; Lindsay JO; Mansfield JC; McGovern D; Parkes M; Pollok RCG; Ramakrishnan S; Rampton DS; Rivas MA; Russell RK; Schultz M; Sebastian S; Seksik P; Singh A; So K; Sokol H; Subramaniam K; Todd A; Annese V; Weersma RK; Xavier R; Ward R; Weedon MN; Goodhand JR; Kennedy NA; Ahmad T;
JAMA; 2019 Feb; 321(8):773-785. PubMed ID: 30806694
[TBL] [Abstract][Full Text] [Related]
24. A Simple Method for TPMT and ITPA Genotyping Using Multiplex HRMA for Patients Treated with Thiopurine Drugs.
Skrzypczak-Zielinska M; Borun P; Bartkowiak-Kaczmarek A; Zakerska-Banaszak O; Walczak M; Dobrowolska A; Kurzawski M; Waszak M; Lipinski D; Plawski A; Slomski R
Mol Diagn Ther; 2016 Oct; 20(5):493-9. PubMed ID: 27307154
[TBL] [Abstract][Full Text] [Related]
25. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression.
Zelinkova Z; Derijks LJ; Stokkers PC; Vogels EW; van Kampen AH; Curvers WL; Cohn D; van Deventer SJ; Hommes DW
Clin Gastroenterol Hepatol; 2006 Jan; 4(1):44-9. PubMed ID: 16431304
[TBL] [Abstract][Full Text] [Related]
26. Real-world NUDT15 genotyping and thiopurine treatment optimization in inflammatory bowel disease: a multicenter study.
Makuuchi M; Kakuta Y; Umeno J; Fujii T; Takagawa T; Ibuka T; Miura M; Sasaki Y; Takahashi S; Nakase H; Kiyohara H; Tominaga K; Shimodaira Y; Hiraoka S; Ueno N; Yanai S; Yoshihara T; Kakimoto K; Matsuoka K; Hayashi R; Nanjo S; Iwama I; Ishiguro Y; Chiba H; Endo K; Kagaya T; Fukuda T; Sakata Y; Kudo T; Takagi T; Takahashi K; Naganuma M; Shinozaki M; Ogata N; Tanaka H; Narimatsu K; Miyazaki H; Ishige T; Onodera M; Hashimoto Y; Nagai H; Shimoyama Y; Naito T; Moroi R; Shiga H; ; Kinouchi Y; Andoh A; Hisamatsu T; Masamune A
J Gastroenterol; 2024 Jun; 59(6):468-482. PubMed ID: 38589597
[TBL] [Abstract][Full Text] [Related]
27. Correlation of genotypes for thiopurine methyltransferase and inosine triphosphate pyrophosphatase with long-term clinical outcomes in Korean patients with inflammatory bowel diseases during treatment with thiopurine drugs.
Jung YS; Cheon JH; Park JJ; Moon CM; Kim ES; Lee JH; Kim SW; Kim JH; Hong SP; Kim TI; Kim WH
J Hum Genet; 2010 Feb; 55(2):121-3. PubMed ID: 19960028
[TBL] [Abstract][Full Text] [Related]
28. Genotyping NUDT15*3 rs1166855232 reveals higher frequency of potential adverse effects of thiopurines in Natives and Mestizos from Mexico.
Texis T; Guzmán-Cruz C; Rodríguez-Dorantes M; Sánchez-García S; Mino-León D; Gonzalez-Covarrubias V
Pharmacol Rep; 2022 Feb; 74(1):257-262. PubMed ID: 34091879
[TBL] [Abstract][Full Text] [Related]
29. TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease.
Stocco G; Martelossi S; Barabino A; Fontana M; Lionetti P; Decorti G; Malusà N; Bartoli F; Fezzi M; Giraldi T; Ventura A
Dig Liver Dis; 2005 Dec; 37(12):940-5. PubMed ID: 16202677
[TBL] [Abstract][Full Text] [Related]
30. TPMT and ITPA genetic variants in Lithuanian inflammatory bowel disease patients: Prevalence and azathioprine-related side effects.
Steponaitiene R; Kupcinskas J; Survilaite S; Varkalaite G; Jonaitis L; Kiudelis G; Denapiene G; Valantinas J; Skieceviciene J; Kupcinskas L
Adv Med Sci; 2016 Mar; 61(1):135-40. PubMed ID: 26674571
[TBL] [Abstract][Full Text] [Related]
31. Nucleoside diphosphate-linked moiety X-type motif 15 C415T variant as a predictor for thiopurine-induced toxicity in Indian patients.
Shah SA; Paradkar M; Desai D; Ashavaid TF
J Gastroenterol Hepatol; 2017 Mar; 32(3):620-624. PubMed ID: 27416873
[TBL] [Abstract][Full Text] [Related]
32. NUDT15 variant is the most common variant associated with thiopurine-induced early leukopenia and alopecia in Korean pediatric patients with Crohn's disease.
Lee YJ; Hwang EH; Park JH; Shin JH; Kang B; Kim SY
Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):475-8. PubMed ID: 26735160
[TBL] [Abstract][Full Text] [Related]
33. No induction of thiopurine methyltransferase during thiopurine treatment in inflammatory bowel disease.
Lindqvist M; Hindorf U; Almer S; Söderkvist P; Ström M; Hjortswang H; Peterson C
Nucleosides Nucleotides Nucleic Acids; 2006; 25(9-11):1033-7. PubMed ID: 17065060
[TBL] [Abstract][Full Text] [Related]
34. Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics.
Chang JY; Cheon JH
Dig Dis Sci; 2019 Sep; 64(9):2395-2403. PubMed ID: 31290039
[TBL] [Abstract][Full Text] [Related]
35. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
Coenen MJ; de Jong DJ; van Marrewijk CJ; Derijks LJ; Vermeulen SH; Wong DR; Klungel OH; Verbeek AL; Hooymans PM; Peters WH; te Morsche RH; Newman WG; Scheffer H; Guchelaar HJ; Franke B;
Gastroenterology; 2015 Oct; 149(4):907-17.e7. PubMed ID: 26072396
[TBL] [Abstract][Full Text] [Related]
36. The impact of thiopurine-S-methyltransferase genotype on the adverse drug reactions to azathioprine in patients with inflammatory bowel diseases.
Hlavaty T; Batovsky M; Balakova D; Pav I; Celec P; Gregus M; Zakuciova M; Hlista M; Horakova M; Desatova B; Koller T; Toth J; Kadasi L; Huorka M;
Bratisl Lek Listy; 2013; 114(4):199-205. PubMed ID: 23514552
[TBL] [Abstract][Full Text] [Related]
37. The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia.
Wahlund M; Nilsson A; Kahlin AZ; Broliden K; Myrberg IH; Appell ML; Berggren A
J Pediatr; 2020 Jan; 216():150-157.e1. PubMed ID: 31635813
[TBL] [Abstract][Full Text] [Related]
38. Adjustment of azathioprine dose should be based on a lower 6-TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers.
Kang B; Kim TJ; Choi J; Baek SY; Ahn S; Choi R; Lee SY; Choe YH
Aliment Pharmacol Ther; 2020 Aug; 52(3):459-470. PubMed ID: 32598049
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenetics of thiopurine therapy in paediatric IBD patients.
De Ridder L; Van Dieren JM; Van Deventer HJ; Stokkers PC; Van der Woude JC; Van Vuuren AJ; Benninga MA; Escher JC; Hommes DW
Aliment Pharmacol Ther; 2006 Apr; 23(8):1137-41. PubMed ID: 16611274
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
